For a middle‑aged adult with rheumatoid arthritis, uveitis, and inflammatory bowel disease on golimumab (Simlandi) undergoing metacarpophalangeal joint fusion, how long should golimumab be discontinued to optimize bone healing, reduce infection risk, and maintain disease control?

Perioperative Management of Golimumab (Simlandi) for MCP Fusion Surgery

Direct Recommendation

Withhold golimumab prior to surgery and plan the procedure when the next dose is due (approximately 4 weeks after the last dose), then restart the medication approximately 14 days postoperatively once the wound shows evidence of healing, sutures are removed, and there is no significant swelling, erythema, drainage, or infection. 1

Rationale and Evidence-Based Approach

Preoperative Withholding Period

• The 2022 ACR/AAHKS guideline conditionally recommends withholding all biologics, including TNF inhibitors like golimumab, prior to surgery and timing the procedure after the next dose is due. 1 This applies to patients with RA, psoriatic arthritis, and ankylosing spondylitis undergoing elective orthopedic procedures.

• For golimumab specifically, which is dosed subcutaneously every 4 weeks, this translates to approximately 4 weeks between the last dose and surgery—allowing one full dosing cycle to elapse. 1

• The orthopedic surgeon's request for 8 weeks off medication exceeds guideline recommendations and may unnecessarily increase the risk of disease flare without additional infection or bone healing benefits. 1

Supporting Evidence on Timing and Infection Risk

• Research on infliximab (another TNF inhibitor) demonstrated that administering the drug within 4 weeks of elective hip or knee arthroplasty was not associated with higher risk of 30-day hospitalized infection or 1-year prosthetic joint infection compared to withholding for 8-12 weeks. 2 This suggests that shorter withholding periods (4 weeks) are adequate for infection risk mitigation.

• The infection risk is more strongly associated with glucocorticoid use >10 mg/day (OR 2.11 for 30-day infection), elderly age, comorbidities, and revision surgery rather than the specific timing of biologic withdrawal. 2

Postoperative Restart Timing

• Restart golimumab approximately 14 days postoperatively once the wound demonstrates healing, sutures/staples are removed, and there is no significant swelling, erythema, drainage, or ongoing infection. 1 This typically occurs around 2 weeks but should be assessed clinically.

• The 14-day timeframe balances early wound healing requirements with the need to prevent disease flare in a patient with multiple autoimmune conditions (RA, uveitis, IBS). 1

Disease Control Considerations

• Golimumab has demonstrated sustained efficacy in RA, psoriatic arthritis, and uveitis through long-term studies, with effectiveness maintained even after temporary interruptions. 3, 4 The drug's once-monthly dosing provides some buffer against rapid disease flare during brief interruptions.

• For this patient with uveitis specifically, golimumab has proven efficacy in controlling JIA-associated uveitis, with studies showing resolution of anterior chamber inflammation and cystoid macular edema. 4 Prolonged withholding beyond 4-6 weeks risks uveitis flare, which can cause permanent vision damage.

• The patient's multiple autoimmune conditions (RA, uveitis, IBD) make disease control particularly critical, as flares in any of these conditions significantly impact quality of life and morbidity. 5, 6

Practical Algorithm

Preoperative:

• Last golimumab dose: 4 weeks before surgery 1
• Surgery timing: When next dose would be due 1

Postoperative:

• Clinical wound assessment at 10-14 days 1
• If wound healing appropriately, sutures out, no infection signs: restart golimumab 1
• If wound complications or infection: delay restart until resolved 1

Total time off medication: Approximately 6 weeks (4 weeks pre-op + 2 weeks post-op) 1

Critical Caveats

• The 8-week postoperative hold requested by the surgeon is not evidence-based and risks disease flare without proven benefit for bone healing or infection prevention. 1, 2 Engage in shared decision-making with the surgeon using guideline evidence.

• Monitor closely for uveitis flare during the perioperative period, as this represents the highest morbidity risk (vision loss) and may require bridging with topical or systemic corticosteroids if inflammation develops. 4

• Glucocorticoid dosing should be continued at the patient's current daily dose rather than stress-dose steroids, as supraphysiologic dosing increases infection risk without benefit. 1

• Hand surgery (MCP fusion) is a smaller procedure than total joint arthroplasty on which guidelines are based, potentially allowing even shorter withholding periods, though extrapolation from major joint surgery guidelines remains the best available evidence. 1